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Introduction
Motor neurone disease (MND; also known as 
amyotrophic lateral sclerosis [ALS]) is a progressive 
neurological disease which leads to increasing paral-
ysis of arms and legs together with speech and swal-
lowing and breathing problems, due to progressive 
muscular weakness. The aetiology is unknown, 
although 5–10% of patients have a family history, 
and for these patients an abnormal gene mutation 
can be found in up to 60%.1 In patients, with no 
family history, the same mutations are found in 10–
20% and there is increasing evidence that there is a 
genetic component, with unknown environmental 
factors, that may lead to the disease.1
The prognosis for most patients is 2–3 years, 
although 25% of patients are alive at 5 years and 
5% at 10 years.2 The progression of the disease is 
very individual, but there is usually progressive 
loss of muscle power, which may affect the limbs, 
the bulbar area – affecting speech and swallowing 
– and the respiratory muscles of the chest wall 
and the diaphragm. The usual cause of death is 
respiratory failure, often associated with infec-
tion. There are now two drugs licensed for MND 
– riluzole, which has been shown to slow the pro-
gression in some patients,3 and edaravone, which 
has been shown to help certain patient groups 
and is licensed in the United States.4
As there is, at present, no cure, palliative care may 
be seen as appropriate from the time of diagnosis, 
particularly as the prognosis is poor. Many patients 
may not be diagnosed for up to 12 months after 
their first symptoms and thus may have developed 
severe disability and may have a short prognosis.
There are many new developments and chal-
lenges in the care of a person with MND, and 
their family – in the communication about the 
disease, the use of interventions in the manage-
ment of symptoms, the issues of exercise and 
physiotherapy, the psychosocial issues faced by 
patient and family and care at the end of life. The 
issues discussed below are of particular signifi-
cance for patients and families and have been 
highlighted within national and international 
guidelines on the provision of care in MND.
The role of palliative care
There has been increasing awareness of the role 
of palliative care for neurological patients5 and in 
particular MND. Over the past few years, there 
have been developments in the care of patients 
with MND – in both the use of interventions, the 
provision of care, the use of guidelines and 
the care at the end of life, which may result in the 
need for careful assessment and discussion with 
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patients and families, when a palliative care 
approach is helpful.
Many guidelines stress the need for palliative care 
including the European Federation of Neurological 
Societies,6 the US Practice Parameter7 and the 
National Institute of Health and Care Excellence 
(NICE) Guideline NG42 Motor neurone disease: 
assessment and management.8 There is also 
increasing discussion of the need for close collabo-
ration between neurology and palliative care ser-
vices, with increasing education of all involved.5
In the past, palliative care was often only provided 
in the later stages of disease progression, near to 
death. However, palliative care is now increasingly 
seen as becoming involved related to the needs of 
the patient and family, rather than estimated prog-
nosis.9 Thus, a patient with MND may need extra 
support at varying times through the disease pro-
gression – at diagnosis when they face an unknown 
disease, as mobility is affected, when gastrostomy 
is discussed, when respiratory function is declin-
ing and non-invasive ventilation (NIV) is dis-
cussed and towards the end of life.10 There may 
be periods between these occasions when the 
needs are reduced and the multidisciplinary team 
(MDT) can continue to support both patient and 
family. The use of triggers, which have been found 
to increase as death approaches, may help the 
end-of-life phase to be identified and may be help-
ful in helping all involved – patient, family and 
professionals – to be aware that death may occur 
in the coming weeks or months.11
There is increasing evidence for the effectiveness 
of palliative care in MND. A study, in a mixed 
group of 50 patients with neurological disease, 
including 16 people with MND, in Turin, Italy, 
showed that the involvement of the palliative 
care team improved quality of life and there was 
clinical improvement in symptoms – pain, dysp-
noea, sleep disturbance and bowel symptoms.12 
Moreover, there was no increased mortality in 
the intervention group, compared with a control 
group, showing that palliative care was safe as 
well as effective.12 Studies on MDT care, which 
will be described later, have also shown that a 
palliative care approach is helpful in improving 
quality of life and prognosis.13,14
There is also increasing evidence that palliative 
care is effective in other neurological diseases, 
which may support the involvement in MND. In 
the care of people with multiple sclerosis (MS), 
studies have shown that there is an improvement 
in symptoms and caregiver burden with early 
short-term palliative care involvement15 and this 
involvement was cost effective.16 A further study 
which involved the education of specialist MS 
nurses to provide extra care did not show an effect 
on quality of life, but did show an improvement in 
symptom burden.17
Systematic reviews of palliative care for all diag-
noses have shown small positive effects on quality 
of life and symptom burden, although many of 
the trials in the meta-analysis were assessed at 
having a high risk of bias.18,19 Other studies have 
suggested that home-based palliative care for 
people with frailty, advanced heart failure, chronic 
obstructive pulmonary disease (COPD) on home 
oxygen, metastatic cancer and severe dementia 
may reduce admissions to hospital, with reduced 
healthcare costs.20 A home-based service in 
Australia has shown that there are reduced hospi-
tal admissions and bed days and reduced costs of 
acute care in the last year of life.21
Thus, there is increasing evidence that palliative 
care should be considered for people with MND 
and the NICE Guideline recommended that pal-
liative care expertise, either expertise of an existing 
MDT member or a specialist palliative care 
professional, should be an integral part of the 
MDT.8 There are still barriers to this involvement 
as there may be fears that the palliative care team 
may have insufficient experience in MND care, 
the load on nursing care may be seen as excessive 
with insufficient resources to meet the need, or 
beds may become ‘blocked’ within specialist pal-
liative care units.10,22 Moreover, many patients, 
families and professionals associate palliative care 
with the end of life and the services may be viewed 
negatively, as they are associated with impending 
death.10,23 There is challenge in explaining the 
earlier role of palliative care to all concerned.
The telling of the diagnosis
As MND has a poor prognosis, palliative care 
may start from the telling of the diagnosis. This 
also provides the opportunity to set the agenda 
for later care. For instance, if the patient and fam-
ily are not given accurate information or receive 
mis-information, such as ‘you will die choking’, 
many fears and anxieties may be engendered.
The NICE guideline recommends that the diag-
nosis should be given by a consultant neurologist 
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with experience and up-to-date knowledge of 
MND and its treatment and care.8 The initial dis-
cussion about MND should be followed up by a 
member of the MDT, so that further questions 
can be answered. A clear single point of contact 
with the MDT was recommended to allow 
patients the opportunity to contact the team for 
further advice and support. The general practi-
tioner of the patient should also be informed, so 
that everyone is aware of the situation.
These recommendations have been supported by 
recent research. In Australia, a survey of neurolo-
gists, patients and families looked at how the 
diagnosis was told, and compared the approaches 
to the SPIKES protocol, which has been sug-
gested as a good way of breaking bad news.24,25 In 
total, 36% of the patients who responded were 
dissatisfied with delivery of the diagnosis. The 
neurologists were graded as those showing high or 
low skills and the main areas where there were 
differences were responding empathetically to the 
feelings of patients and families, sharing informa-
tion and suggesting realistic goals, exploring what 
patients and families were expecting, and making 
a clear plan and following this through.25 In the 
Netherlands, a study showed that the organisa-
tion of two appointments, 10–14 days apart, 
helped patients and families to cope with the 
diagnosis.26 The first appointment provided 
information, the intervening time provided the 
opportunity to re-orientate themselves to the new 
perspective on life and the second appointment 
allowed further discussion of the future plans and 
for the introduction of the MDT.26
Thus, a good approach to the telling of the diag-
nosis allows a partnership approach to be devel-
oped with the MDT so that both patient and 
family feel supported. This will help to establish 
the trust for future care and is a very important 
part of the palliative care of a person with MND. 
However, in a busy neurology clinic, the estab-
lishment of these norms may be challenging.
MDT care
The role of the MDT in the care of patients with 
MND has become clearer and does seem to ben-
efit care. There have been several studies that 
have shown improvement in symptom manage-
ment and prognosis when an MDT is involved. In 
one study, patients under the care of a hospital 
clinic-based MDT were compared to historical 
controls, and the survival was found to be longer 
for those with MDT care - 19 months – com-
pared to 11 months for the control group.13 
Although the effect was augmented by the 
increased use of riluzole, NIV and gastrostomy, 
there seemed to be an independent effect of the 
MDT, although the exact nature of this is 
unclear.13 In a further study in Ireland, patients 
were compared between the Republic of Ireland, 
where an MDT approach is present, and Northern 
Ireland, where a network approach occurs. There 
was a survival benefit of the MDT approach, with 
a survival advantage of 8 months, which again 
was not explained by the increased use of inter-
ventions.14 The studies are both open to criticism 
as they were not randomised controlled trials and 
the control groups may not have been completely 
comparable. However, there does appear to be 
increasing evidence for the effectiveness of the 
MDT approach.
The review of evidence by the NICE guideline 
showed that there was a benefit of the MDT 
approach and an economic assessment showed 
that the incremental cost-effectiveness ratio was 
£26,672 per quality of life year (QALY) gained. 
This was considered to be a cost-effective inter-
vention for a rare disease and was strongly recom-
mended.8 The MDT should involve several 
disciplines and include members with experience 
of MND care – in particular neurologist, special-
ist nurse, dietitian, physiotherapist, occupational 
therapist, respiratory professional, speech and 
language therapist and palliative care expertise, 
either from a trained member of the MDT or a 
specialist palliative care professional.8 Thus, pal-
liative care is seen as important from diagnosis 
and as an integral member of the MDT.
The importance of the MDT has been shown in 
these studies, but it is unclear how this is so effec-
tive. The MDT, as recommended by NICE, 
should be seeing patients regularly, every 2–3 
months, and more often if there are problems and 
less often if the disease is stable. These assess-
ments allow all areas to be considered and all 
members of the MDT to work in a co-ordinated 
way. This regular assessment and involvement of 
the wider MDT would seem to be important and 
further research is needed to elucidate the reasons 
for MDT effectiveness.
The need for continuity of care was also stressed 
within the NICE guideline. As the disease 
progresses, there will be the need for continual 
reassessment and adaptation to these changes. 
Palliative Care: Research and Treatment 12(1)
4 journals.sagepub.com/home/pcr
Patients and families benefit from the MDT 
approach as the same professionals become 
involved as the disease progresses, rather than a 
new professional on each occasion.
Cognitive change
There is increasing evidence of the presence of 
cognitive change in MND and that nerve loss is 
not only found in motor neurones but within the 
brain, and in particular the frontal lobes. Up to 
50% of patients with MND may have cognitive 
impairment7,27 and this may be seen as:
 x Fronto-temporal dementia (FTD) – for up 
to 15% of patients,27 and especially those 
with the C9orf 72 gene mutation (which is 
also associated with FTD alone). There is 
breakdown in cognition, behaviour and 
personality. Memory may be affected in 
varying ways but as FTD progresses there 
are increasing issues – with socially inap-
propriate behaviour, including disinhibi-
tion and gluttony – impairing everyday 
functioning.28
 x ALS bi – behavioural impairment, seen in 
up to 28% of patients7 with evidence of 
frontal lobe dysfunction. Changes in behav-
iour such as self-centeredness, irritability, 
apathy, emotional blunting, loss of embar-
rassment, disinhibition, lack of concern for 
themselves and reduced empathy may be 
seen.28
 x ALS ci – cognitive impairment occurs in up 
to 39% of patients7 and may be seen with 
behavioural changes. These changes may 
be found on testing, but there is increasing 
evidence that they are also clinically rele-
vant. The changes are often in executive 
functioning – including organisation and 
planning, mental flexibility and reduced 
abstract thinking.29
Language impairment may also be seen in some 
patients, with difficulty in generating thoughts or 
finding words. There is increasing evidence for 
changes in emotional processing and the theory 
of mind – where patient may be less able to infer 
the mental state of other people or recognise 
emotions in others.27
All these changes have a profound impact on care. 
The recognition of these changes may be com-
plex, and initially, they may be subtle and not 
appreciated. Families may be aware of changes in 
behaviour and have concerns, and their involve-
ment in recognition of cognitive change is impor-
tant. There are several scales that can be used and 
the Edinburgh Cognitive and Behavioural Screen 
(ECAS) allows an assessment of the various 
aspects of MND cognitive change in 15–30 min 
and includes the questioning of families as well as 
the patient. The ECAS has been shown to be an 
effective screening tool and there are now alterna-
tive versions so that serial assessment may be 
possible.30
The recognition of cognitive change is important 
as this may affect the management and the con-
sideration of treatment and interventions. It is 
thought that cognitive change may be seen early 
after diagnosis and so early screening can be help-
ful in future planning. Decision making may be 
affected if there is profound cognitive change, 
especially as executive function is affected, and so 
advance care planning may be helpful earlier in 
the disease progression, while the person has the 
mental capacity to make decisions. Whenever 
decisions are made, it is important to consider 
capacity and cognition, as some patients may find 
decision making very difficult and careful discus-
sion when decisions are made will be needed. A 
best interest decision may be needed to be taken 
by the lead practitioner, in conjunction with the 
MDT, patient and family.31
There are increased stresses on the family and 
carers when coping with FTD or cognitive 
change. Caregivers report increased depression 
and anxiety and caregiver burden is increased. 
This is affected by behavioural change and physi-
cal impairment.32 Explanation is needed to help 
caregivers, family and professionals understand 
the behaviour and to undertake strategies to cope 
with the changes, such as limiting decisions to 
two clear options.27,32
Professionals need to consider cognitive func-
tion when discussing management, particularly 
in the consideration of interventions such as 
NIV or gastrostomy. Cognitive change may 
make it very hard for a patient to tolerate any 
intervention and a Dutch study showed that 
patient with behavioural changes received NIV 
less often than other patient groups.33 Moreover, 
the survival of patients with frontotemporal cog-
nitive change was reduced compared to other 
patients – with a median survival of 3.4 years 





Over the last 20 years, there has been increasing use 
of interventions in MND, in particular NIV and 
gastrostomy. These have a significant effect on 
quality of life and maybe length of life, but also raise 
ethical issues as the disease continues to progress.
Ventilatory support
The majority of patients, as they deteriorate, 
develop weakness of the diaphragm and respira-
tory chest wall muscles. This may cause dyspnoea 
and will lead to respiratory failure.34 The initial 
evidence for respiratory failure will often be at 
night, when the diaphragm is less able to move 
easily when lying down and the respiratory mus-
cles may be more relaxed, causing the symptoms 
of orthopnoea, poor sleep, regular wakenings (due 
to episodes of low oxygen as a result of hypoventi-
lation), excessive dreaming (as arousal interrupts 
rapid eye movement [REM] sleep), morning 
headache (due to carbon dioxide retention), feel-
ings of never being refreshed, anorexia and even 
personality change.34 On examination there may 
be signs of increased respiratory rate, orthopnoea, 
weak voice and cough, the use of accessory mus-
cles of respiration, reduced chest wall movement 
and paradoxical movement of the abdomen.34 
More rarely patients may present with respiratory 
muscle weakness and even in respiratory failure.35 
Initially, the symptoms and signs of MND are 
often missed, often due to misdiagnosis.36 The 
diagnosis of MND may only be made after initial 
resuscitation, and ventilator support has been 
commenced.35 This occurs rarely and usually 
patients remain ventilator dependent.35
NIV has been shown to be effective in reducing 
symptoms, improving quality of life and extending 
life. There has been one randomised controlled 
trial showing an improvement in several measures 
of quality of life and a median survival benefit of 
205 days – those receiving NIV had a median sur-
vival of 216 days opposed to 11 days who just 
received best supportive care.37 However, not all 
patients are able to tolerate NIV and may experi-
ence problems with the use of technology, sleep 
disturbance, the sensation of pressure and pulsing, 
dry mouth and mask concerns, including claustro-
phobia while wearing the mask.38 However, many 
patient and families do find NIV to be beneficial, 
with increased energy, improved sleep, improved 
breathing, better speech and improvement in car-
egivers’ well-being.34,37 Patients with bulbar issues 
were found to have a poorer outcome when using 
NIV37 and those with cognitive change or FTD 
may have considerable difficulty in coping with the 
equipment and the restriction with NIV.39
The discussion and consideration of NIV is com-
plex, and palliative care professionals may be able 
to offer the opportunities for these discussions. 
Moreover, there is the need to discuss what will 
happen in the future, for although these symp-
toms of respiratory failure may improve, the dis-
ease will continue to progress, with increasing 
disability. It is very helpful for these discussions to 
take place early in the disease progression, before 
there is an urgent need to start NIV, so that time 
can be taken in the discussion and decision mak-
ing. The NICE guideline suggests that the use of 
NIV should be discussed when respiratory func-
tion is assessed, and this should start from early in 
the disease and soon after diagnosis so that early 
changes can be detected.8 The Guideline also rec-
ommends that when NIV is started, there is the 
need to discuss the advantages and disadvantages 
of NIV and the possibility of becoming depend-
ent on NIV, when the disease has progressed with 
increased disability.8 Discussion of the future and 
the future planning is essential so that patients 
can state they would wish if there was further 
deterioration,8 as advance care planning – which 
ensures the patient’s wishes are known, while 
they have capacity, so that if capacity is lost later 
their wishes can be respected.31
As the respiratory function continues to deterio-
rate, the use of NIV may increase. Initially, the use 
is at night, when the patient is lying down, but 
there may be a need for NIV during the day and 
over time some patients become totally dependent 
on NIV and are only able to tolerate removal for a 
short time, for eating or hygiene care. This may 
lead to complex decision making, as the patient 
may ask to stop NIV. If they are dependent on 
NIV, removal could cause severe symptoms of 
breathlessness and distress40 and so medication is 
often needed to relieve distress and manage 
breathlessness before withdrawal.40 Patients who 
are not 24 h dependent may still experience dis-
tress at withdrawal and require medication.
Palliative care services may have a role in helping 
to facilitate the discussion and decision making at 
this time. If the patient has full capacity to make 
decisions, then there are no ethical or legal barriers 
to stopping this intervention, in the United 
Kingdom and many other countries. If a patient 
does not have capacity for the decision, as may 
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occur with cognitive change of FTD, a ‘best inter-
ests’ decision may need to be made by the lead 
medical practitioner, in consultation with the wider 
MDT and the family. The MDT may also need to 
take into account any advance care plan made by a 
patient earlier, when they did have capacity, and in 
particular a well-defined Advance Decision to 
Refuse Treatment (ADRT) which may clearly 
define when a patient would wish to stop NIV.
However, there are many practical aspects to be 
considered, and although the action is ethical for 
many people, the cessation of a treatment, and 
the ensuing death of the patient within a short 
time, can feel as if they have caused the death. A 
survey of palliative medicine consultants in the 
United Kingdom found that they found the dis-
cussion of the procedure, the varying team reac-
tions and the practical, ethical and emotional 
aspects all very difficult. They were asked to rate 
how challenging they found these decisions, with 
a scale from 1 - not at all challenging – to 10 - very 
challenging. In total, 32% rated the practical 
aspects at over 7 out of 10, 33% rated the ethical 
aspects at over 7 out of 10 and 49% rated the 
emotional challenge at over 7 out of 10.41 Further 
studies have confirmed that this is a difficult 
and complex area for professionals42 and the 
Association for Palliative Medicine of Great 
Britain and Ireland has produced a guidance for 
professionals, in association with other profes-
sional bodies.40 This outlines the ethical and legal 
position and provides a clear plan for the proce-
dure and support from mentors who have been 
involved in the withdrawal of NIV in the past.40
One challenging and developing area is the 
increasing discussion of the role of tracheostomy 
and invasive ventilation. In the United Kingdom, 
this is rare and often only occurs before the diag-
nosis is known, such as when a person presents in 
acute respiratory failure. Some patients may wish 
to consider tracheostomy as an elective proce-
dure, particularly if they have severe problems 
with secretions or they cannot tolerate NIV. 
There is evidence that tracheostomy tends to be 
chosen by younger patients and those who are 
wanting to stay alive.43
The rate of tracheostomy across the World varies 
greatly, with the United Kingdom at only 1–2%, in 
some areas of Italy 10–30%44 and in Japan over 
30% of all patients with MND have a tracheos-
tomy and many live for up to 10–20 years.34 
Although tracheostomy may reduce the problems 
of secretions and aspiration, there is the risk of 
increased disability, reduced communication and 
even, in up to 15%, becoming ‘locked in’ with no 
way of communicating.45 Moreover, there is evi-
dence that although the quality of life of the patient 
may be maintained, many caregivers find the bur-
den very great, and in one study 30% of carers 
rated their own quality of life lower than that of the 
patient.46 The prognosis after tracheostomy is 
unclear, but in European studies, the median sur-
vival was 24 months in Italy44 and 56 months in 
Denmark43 but with a large range in all areas. The 
issues of withdrawal of ventilation may have to be 
faced, as with NIV, and the death will usually 
occur shortly after ventilation is removed.
There are many issues that need to be considered, 
and it is very helpful for these discussions to start 
before a decision is needed, so that time can be 
taken for discussion and consideration of the pos-
itive and negative aspects. The NICE guideline 
suggests that monitoring of respiratory function 
should be undertaken from diagnosis and that 
discussion of the role of NIV, the benefits and 
drawbacks can be introduced over months and 
years, rather than a rushed decision when some-
one is very breathless, distressed and intervention 
needs to take place urgently.8 All too often trache-
ostomy may occur in these urgent scenarios and 
be regretted later.47
Cough management
Respiratory muscle weakness affects the ability to 
have an effective cough. Normally, the inspiratory 
muscles increase lung volume, expiratory muscles 
produce the increased thoraco-abdominal pres-
sure and the upper airway muscles co-ordinate 
glottis closure and opening, allowing a cough. All 
of these aspects may be affected to a varying 
degree in MND.48 A reduced cough reduces the 
clearance of secretions and increases the risk of 
respiratory infection. It has been suggested that a 
peak cough flow of 160 L/min is necessary to 
clear the airway, and if patients’ peak cough flow 
is less than 270 L/min, they should be taught 
cough augmentation techniques, to ensure that 
they can clear debris and cope with an infective 
episode, when the cough is usually reduced.48
There are several techniques that can be used and 
the NICE guideline recommends that manual 
assisted cough techniques should be offered to 
patients who cannot cough effectively.8 Breath 
stacking or assisted breath stacking, using a lung 
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volume recruitment bag, is recommended as the 
initial treatment options, although there is little 
evidence in the literature.8 These techniques allow 
the patient to maximise the volume of air they can 
inhale and then to cough with an increased cough 
pressure.49 There may be difficulty if there are 
bulbar issues and the patient and family will need 
careful education in the technique.
The use of a mechanical insufflator-exsufflator has 
also been suggested.34 There is little evidence that 
this is more effective for many patients and it is 
expensive and some patients find the pressures dif-
ficult to cope with. The NICE guideline does rec-
ommend considering a mechanical cough assist 
device if breath stacking is not effective or during a 
respiratory tract infection.8 This has been sup-
ported by a study showing that there is deteriora-
tion in respiratory muscle strength in an infective 
episode and the mechanical insufflator-exsufflator 
was effective for 83% of patients in an infective 
episode, compared to 35% with manually assisted 
coughing.50
Careful assessment of the ability to cough, and 
the peak cough flow is important, particularly for 
the patient starting on NIV. The use of tech-
niques to aid coughing and the consideration of a 
mechanical insufflator-exsufflator may be neces-
sary, particularly during an infective episode, and 
may prevent hospitalisation.
Gastrostomy
The maintenance of nutrition in the care of a per-
son with MND has developed over recent years. 
The assessment of the nutritional status of patients 
is important and should be part of the regular 
MDT assessment, including measurement of 
weight and the assessment of diet and swallowing, 
nutritional input, fluid intake, oral health and 
swallowing.8 There is a real challenge to profes-
sionals to be more aware of the nutritional state of 
patients, as even weight loss of 5% appears to be 
associated with increased mortality.51 Further 
studies are being undertaken to look at the bene-
fits or risks of increased feeding, even in the early 
stages of the disease. The concerns about nutri-
tion have increased the consideration of interven-
tions to maintain weight and well-being.52
Reduced nutritional input may be due to swallow-
ing issues but also could be related to arm weak-
ness (if that the person is less able to feed 
themselves), respiratory issues (with breathlessness 
on eating), or depression or low mood. An MDT 
assessment will allow for the provision of eating 
aids to help the person take food and drink into the 
mouth or for help with the preparation of food, so 
that it remains nutritious and is also appealing and 
tasty. Advice may also be necessary to help with 
the positioning, seating and posture for meals, as 
neck weakness may cause swallowing to be diffi-
cult. Alternative feeding may be considered, often 
using food in a ‘custard’ consistency or the use of 
thickeners or nutritional supplements. The role of 
eating in social situations needs to be considered, 
as issues of swallowing or in eating may lead to the 
person eating less due to embarrassment in social 
situations, such as at a family meal or when eating 
out. Fear of aspiration or choking may affect a per-
son eating, and a wider discussion may be 
required.8
The use of gastrostomy – as a percutaneous endos-
copy gastrostomy (PEG), percutaneous radiologi-
cally inserted gastrostomy (PRG) or per-oral 
image-guided gastrostomy (PIG) – has increased 
over the last few years. There is mixed evidence of 
the effectiveness of gastrostomy on survival, but 
there is evidence that there may be a positive effect 
on quality of life and survival.52 The timing of gas-
trostomy insertion is complex. The risks of inser-
tion are related more to respiratory function than 
swallowing or nutritional aspects, as there are 
increased risks of insertion of a PEG if the forced 
vital capacity (FVC) is less than 50% of expected.7 
The concerns may be less if a PRG or a PIG is 
used, as sedation may not be necessary and the 
patient does not need to be recumbent.
These discussions about gastrostomy may need to 
start when swallowing is starting to cause problems 
and respiratory function is deteriorating.8 This 
may feel too early for the patient but an earlier 
insertion is safer and less likely to lead to complica-
tions. The gastrostomy does not need to be used 
initially but may be used over time to supplement, 
rather than totally replace, oral feeding, particu-
larly when swallowing is more difficult, such as 
during an infection. The use may increase slowly 
and be used as required. A gastrostomy may also 
facilitate care at home, as nutrition, hydration and 
medication can be continued more easily, which 
may allow a patient to remain, and die, at home.53
The discussion may be complex. A study has 
shown that people who were more likely to make 
decisions compared to others were found to have 
a higher IQ, longer education, an ‘active approach’ 
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to gastrostomy and NIV and actively seeking 
information, services and interventions.39 Another 
important factor in decision making is the 
patient’s pleasure in eating and it is very impor-
tant to stress to patients that some oral feeding, 
for taste and pleasure, can continue with the gas-
trostomy used for supplementary feeding. Patients 
with evidence of cognitive dysfunction were also 
less likely to accept a gastrostomy and so careful 
assessment of cognition should be included when 
decisions are made.39 The study also shows the 
importance of ensuring that patients and families 
do understand the decisions and the implications 
of an intervention, with extra care needed if the 
education level, IQ, understanding of the disease 
and social support are reduced.39 Medical and 
allied healthcare professionals may hold different 
attitudes to interventions and this can affect deci-
sion making. Thus, there is a challenge to ensure 
nutritional aspects are assessed and options dis-
cussed appropriately. These discussions do need 
to be undertaken earlier in the disease progres-
sion, so that there is time for the decision process 
and a sudden decision, during a crisis or when 
swallowing has become very difficult, is avoided.
Weakness and the role of exercise
A person with MND faces increasing muscle 
weakness and reducing functional ability and chal-
lenges the professional team. There is little evi-
dence that physiotherapy or other activity can 
prevent these changes, although resistance exer-
cise and range of motion exercise may reduce 
pain, cramps with some improvement in function, 
as measured by the ALSFRS scale.54 Resistance 
and endurance exercise have also been shown to 
be safe and does not worsen function.55 The NICE 
guideline has recommended exercise programmes 
to maintain the range of joint movement, prevent 
contractures, reduce stiffness and discomfort and 
to optimise function.8 Family members and carers 
should help in any exercise programme and the 
patient and family may also benefit from advice on 
safe manual handling.
Neck weakness may cause particular distress to 
patients, as this may cause pain across the neck, 
affect breathing, communication and eating, 
increase drooling and affect quality of life, as 
the patient is less able to look at their environ-
ment and be involved in social contact. There 
have been many different collars to help with this 
head drop but all have problems – reducing mobil-
ity, increasing stiffness and pain and they are often 
very obtrusive. A new collar – Head-up – has 
recently been developed following a careful assess-
ment and development project.56,57 This does sup-
port the neck but can be adjusted to cope with the 
individual’s needs, is less likely to cause discom-
fort and is aesthetically more acceptable.56,57
Psycho-social aspects of care
The psychological support of the person with 
MND is very important. They face multiple, con-
tinual loss – of speech, swallowing, movement, 
mobility, cognition, emotional expression, social 
interaction – and face dying and death. The MDT 
should discuss the emotional and psychological 
aspects of care at all appointments,8 and this may 
include the wider understanding of MND and its 
effects on daily living, the acceptance of the diag-
nosis, adjustments to changes in work, lifestyle 
and their usual activities, changes in family roles 
and sexuality/intimacy and their own concerns 
about their family. Ongoing support is essential, 
and the opportunity to discuss these issues is 
important, with someone who does know about 
MND and its implications.
There would seem to be no specific psychosocial 
interventions for people with MND and a study 
of a group of therapists suggested that their main 
aims were to support the person in the ‘here and 
now’, focus on what they were able to do, re-
affirm the person in their ability to maintain a role 
in life and support the person in exploring their 
emotions.58 It is important for the therapist to 
have an understanding of MND and how it 
may affect someone.58 The provision of clear 
information, clear communication and address-
ing fears and uncertainty are important.59 A 
MND Advisory Service in Australia provided 
home visits and telephone support for patients 
and families and was greatly valued, with both 
groups feeling more supported and more able to 
make informed decisions.60
Depression is seen more commonly in MND, 
particularly in patients over 65 years and in the 
first year after diagnosis.61 Rates in studies vary 
from 4.4%61 to 12%.62 The use of antidepres-
sants was also higher in MND, although tricyclic 
antidepressants may also be given to help with 
drooling. Although the wish to die was common, 
with 25% of patients expressing these wishes, 
the majority did not have depression, with only 




Family caregivers have been shown to have many 
issues, which are often not recognised. They may 
have to cope with many areas, particularly as 
the disease progresses. A study of caregivers in 
Norway showed that they felt there were five 
predominant areas of concern – immediate 
care work, seeking information about MND, 
managing competing obligations, maintaining 
normality, and managing external resources and 
assistance.63 It was complex to balance all these 
areas and issues, while providing increasing care 
for the person with MND.
There is appreciable burden of care on family car-
egivers. This may be increased if there are social 
restrictions due to caring for the patient, self- 
criticism of their caring and anger and frustration 
at the various situations, often associated with 
guilt about the situation they face in caregiv-
ing.64,65 Moreover, there is increasing evidence 
that these burdens are greater when the patient is 
more disabled physically and there are behav-
ioural issues, associated with cognitive change.32
The awareness of possible caregiver burden is 
important in providing care to both patient and 
family. It is important to ensure that interventions 
do not increase the burden of carers, this again 
emphasises the importance of ensuring that there 
is consistent care from caring support services.8 
The NICE guideline recommended that social 
care should be undertaken by people who know 
about the disease and this care should continue 
with a small team of people known to the patient 
and family, to allow continuity of care and famili-
arity with the needs of the patient.8 Many families 
feel that they spend most of the time they receive 
from carers in explaining the issues and needs of 
the person. This is reduced by the provision of 
a small, consistent team.8
It may be useful to undertake regular assessment 
to identify family support needs and thus allow 
the most appropriate and helpful support. The 
Carer Support Needs Assessment Tool (CSNAT) 
has been shown to identify the priority areas for 
support and the tool was well accepted by car-
ers.66 A study using CSNAT showed that the 
main priorities were support for future care, hav-
ing a contact when concerned and the provision 
of equipment to help in care.10
Thus, the wider assessment of the whole patient 
and whole family, which is an implicit part of pal-
liative care, is a vital part of the care of someone 
with MND and continual assessment and discus-
sion is needed.
End-of-life care
As MND has no curative treatment and has a 
prognosis for many of only 2–3 years, end-of-life 
issues may need to be considered early in the dis-
ease progression, particularly as there may be 
delays in diagnosis so that the disease has pro-
gressed by the time the diagnosis has been made. 
There is evidence that patient and families do 
appreciate the discussion of end-of-life issues10 
and the NICE guideline recommended that end 
of life should be discussed if the patient or family 
ask and when considering and commencing new 
interventions, such as gastrostomy and NIV.8
However, there is often reluctance to discuss the 
issues of dying and death, although many patients 
and families have great concerns about the future. 
There are many myths that dying of MND is ‘dis-
tressing’ and ‘horrendous’ and is ‘due to chok-
ing’. There has been widespread publicity when 
certain cases are discussed in the UK Courts, 
when people have asked for the right to an assisted 
death.67 There is increasing evidence that death 
for MND is usually peaceful and studies have 
shown that choking of death is rare – in a study of 
patients at St Christopher’s Hospice in London 
only one patient died choking, and this was in 
1968 soon after the hospice opened;68 in a further 
study of 121 patients in the United Kingdom and 
Germany, no patient died choking and over 88% 
patients died peacefully.69
These myths need to be confronted and evidence 
provided that death can be peaceful.68,69 A study 
in France has shown that the majority of patients 
died of respiratory failure (77%) and 10% died of 
other causes – post surgical or trauma (5%), car-
diac disease (3.4%), suicide (1.3%) or unknown 
causation (0.7%).70 However, there were many 
patients, in particular those dying outside of hos-
pital, where the cause could not be elucidated. 
The use of interventions had continued until near 
to death in many patients - 55% were still taking 
riluzole, 33% were on NIV and 37% had a gas-
trostomy in use.70 In Hong Kong, a study of 
52 patients recorded the main causes of death as 
pneumonia (54.8%) and respiratory failure 
(40.5%).71 Thus, the evidence does show that 
death is usually peaceful and a distressing death is 
rare – and no different for dying from other 
diseases.
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However, the issues of dying and death should be 
discussed with patients, particularly as interven-
tions such as NIV and gastrostomy are intro-
duced.8 As discussed above, the withdrawal of 
treatment may need to be considered – at the 
patient’s request or in response to advance care 
planning. Patients and families may wish to discuss 
these issues and both patients and families may 
vary between acceptance and hope.60 The oppor-
tunity for families to talk and share experiences 
together is important and facilitating this sharing 
may become the role of anyone in the MDT.72
Caregivers may have specific issues. It has been 
suggested that the issues that family caregivers 
face are the conflicts of trying to prepare for the 
future while they feel overwhelmed by the issues 
of caring throughout the illness progression and 
coping with uncertainty.10 Family caregivers 
talked of the themes of coping with the ‘Here and 
Now’ – with the privilege of caregiving, the all-
consuming nature of care, coping with family 
cohesion and conflict and the difficulties of cop-
ing with variable health and social care support; 
negotiating with the Here/After – with a unpre-
dictable trajectory of disease progression, trying 
to prepare but being unable to plan and preparing 
while living with both hope and fear and feelings 
of self-reproach when thinking of the future.10 
Thus, many caregivers may be prepared cogni-
tively, some were prepared behaviourally but 
many found preparing emotionally challenging. 
Thus, professionals should not assume that all are 
well prepared for the future, and death, and need 
to carefully assess each family.10
The discussion of future care, including dying 
and death, will also enable the opportunity for 
advance care planning – expression of the per-
son’s wishes for future care which can influence 
decisions if the person loses the ability to make 
the decision themselves, due to loss of communi-
cation or cognition. This is particularly important 
to consider for people with MND as both com-
munication and cognition may be affected, par-
ticularly near to the end of life. The person may 
express their wishes as to the interventions they 
may not wish, such as cardiopulmonary resuscita-
tion, tracheostomy, gastrostomy, ventilator sup-
port, place of care or death, their financial wishes 
in the form of a will, funeral arrangements or the 
overall care at the end of life, such as specific 
wishes for music or family/friends to be present 
at the time of death.31 In the United Kingdom, 
a person can make a specific ADRT, which if 
specific and stating that the person realises that 
the decision could lead to their death is legally 
binding, or a Lasting Power of Attorney, where 
other people are chosen, who would make deci-
sions on the person’s behalf.31 These only apply if 
the person has lost capacity to make the decision, 
for if they are able to decide for themselves they 
should be enabled to make the decision. Other 
aspects of care at the end of life may also need to 
be considered, and it is important to ensure that 
there is clear understanding about these issues, 
as for instance there is evidence that place of 
care and place of death may be seen as separate 
decisions and need to be clarified clearly and 
separately.73
Some patients with MND may wish to discuss 
hastening of death – by euthanasia or physician-
assisted suicide. In countries where this is legal, 
there is evidence that people with ALS do chose 
an assisted death more often than other people – 
in Oregon the rate of physician-assisted suicide 
was 374.5/10,000 compared to 61.0/10,000 for 
cancer74 and in the Netherlands about 20% of 
patients with ALS receive euthanasia compared 
to 5% of cancer patients or 0.5% of heart failure.75 
When a patient does discuss hastening death, this 
is an opportunity to discuss the reasons behind 
the request – which may be fear of being ‘kept 
alive’ by ventilation, fear of the dying process or 
fear and concerns about death itself.23 It may be 
possible to address some of these issues and the 
desire for a hastened death may reduce.23 
However, some people may wish to strongly 
express their autonomy, and in legislations where 
no action can be taken, there is a continued need 
to support the patient and family and see if any 
further discussion may be helpful.
There is often the need to recognise when the end 
of life is approaching for someone with MND. 
The deterioration may be rapid, often with an 
infection or a sudden deterioration in respiratory 
function.11 There is evidence that there may be 
triggers which may indicate when the end of life is 
near for neurological patients: swallowing prob-
lems, recurring infection, particularly aspiration 
pneumonia, marked decline in functional status, 
cognitive difficulties, weight loss and significant 
complex symptoms.11 For people with MND, 
further triggers were suggested: respiratory failure 
or increased breathlessness, reduced mobility and 
dysphagia.11 Although these triggers were agreed 
by expert consensus, studies have shown that the 
number of triggers increases nearer to death and 
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patterns of symptoms may be seen.76 Thus, these 
triggers may be useful, in conjunction with a 
wider assessment of the patient, by identifying 
when death may be near, so that the care pro-
vided may be adjusted – such as careful consid-
eration of interventions such as continuation of 
NIV or gastrostomy feeding, provision of antici-
patory medication, for use at home in a crisis situ-
ation, and fuller discussion with the patient, if 
appropriate, family and the wider MDT.
Conclusion
All patients with MND will benefit from palliative 
care and all involved in patient care should be 
able to provide a palliative care approach – listen-
ing to the patient and family and assessing and 
managing issues – physical, psychosocial and 
spiritual.77,78 Some patients and families may 
have more complex needs and a specialist pallia-
tive care team approach – from a specialist unit/
hospice – may be helpful. This team will have 
greater expertise, have had specialist training and 
continuing education.77,78
There will need to be a collaborative approach 
involving many services – including primary/fam-
ily/home care but many specialist services, such as 
gastroenterology, respiratory medicine, neuropsy-
chology as well as neurology and palliative care 
services. It is important to ensure that these 
services provide co-ordinated care and many sug-
gest a specific/key person or team with whom the 
patient and family can have regular contact.8,9  
It is also important to acknowledge that different 
teams will act in different ways and may have var-
ying ways of collaboration and differing ethos;79  
if these differences are acknowledged, the care 
for the patient and family is likely to be better 
co-ordinated and effective.79
Increasingly, particularly in the United States, 
neuro-palliative care is developing aiming to pro-
vide the specialist MDT approach.80 This may 
develop further, but in many areas, there will be 
the need to develop a close collaboration between 
neurology and palliative care so that all patients 
with MND can receive the most appropriate and 
effective care, maintaining quality of life and 
allowing a peaceful death.
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